FLAG方案治疗成人难治复发急性白血病20例临床观察

目的 探讨FLAG方案(氟达拉宾、阿糖胞苷和非格司亭联合应用)治疗成人难治复发急性白血病(acute leukemia,AL)的疗效及不良反应.方法 对20例成人难治复发AL患者采用FLAG方案化疗,观察疗效及其不良反应.氟达拉宾50mg/d,静脉滴注,持续30 min,第1～5天；阿糖胞苷0.5～1.0 g/(m2·...

The therapeutic effect of FLAG regime for refractory or relapsed acute leukemia

Objective To investigate the efficacy and side effects of the regimen combined with fludarabine,cytarabine and filgrastim(FLAG)for refractory or relapsed patients with acute leukemia(AL).Methods A total of 20 patients with AL were enrolled to treat with FLAG regimen,then observed the efficacy and side effects.Fludarabine 50 mg/d,intravenous drip(VD) lasts 30 min 1-5 days.Cytarabine 0.5―1.0 g/m(2) on day 1,every 12 hours at a time,after the fludarabine 4 h,VD,1-5 days.Filgrastim 300 μg/d,subcutaneous injection(fludarabine before 1 h,0-5 days).Results The rate of CR,PR and OR was 55%,20% and 75% respectively.71.8% of CR occurred after the first course with such regimen.There were no disparities between the groups of ALL,AML and MAL(P>0.05).The main side effects were severe myelosuppression and infection due to neutropenia.But mostly patients could be recovered after treatment during the intermission.Conclusion FLAG regimen is effective and well-tolerated treatment for patients with refractory and relapsed acute leukemia,especially for younger patients.It is one of the prefered regimens to treat refractory or relapsed acute leukemia.